Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01011439 |
Recruitment Status :
Terminated
(For the 2 last patients still on treated nominal therapeutic use of the Milciclib was approved at INT Milano.)
First Posted : November 11, 2009
Results First Posted : October 16, 2018
Last Update Posted : February 6, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thymic Carcinoma | Drug: Milciclib Maleate | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 72 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy |
Actual Study Start Date : | February 22, 2010 |
Actual Primary Completion Date : | May 31, 2017 |
Actual Study Completion Date : | December 17, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Milciclib Maleate (PHA-848125AC)
100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
|
Drug: Milciclib Maleate
150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle. Number of cycles: until disease progression or unacceptable toxicity. Other Name: PHA-848125AC |
- Progression-free Survival Rate at 3 Months [ Time Frame: 3 months since treatment start ]The proportion of successes (i.e. patients alive and progression free at 3 months since treatment start) out of the total number of evaluable patients
- Confirmed Objective Response Rate (ORR) [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Point and 95% confidence interval estimates was calculated for the objective tumor response rate (confirmed CRs or PRs). The determination of antitumor efficacy was based on objective tumor assessments made according to the RECIST guideline (version 1.1) The analysis was performed in the evaluable population.
- Disease Control Rate [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Point and 95% confidence interval estimates was calculated for the disease control rate (confirmed CRs / PRs and SD>/= 6 weeks). The analysis was performed in the evaluable populations.
- Progression-free Survival [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works.
- Duration of Response [ Time Frame: Assessments were made every 6 weeks from start date until PD to a maximum duration of 242 weeks or until PD. ]Assessed in patients achieving a confirmed objective tumor response by RECIST version 1.1 criteria.
- Overall Survival [ Time Frame: Every 6 weeks during Follow-Up until PD or new therapy start; every 6 months thereafter, up to 2 years from the last dose of study drug. ]The length of time from the start of treatment for a disease, such as cancer, to the date in which the patients diagnosed with the disease were still alive.
- Overall Safety Profile (Adverse Events (NCI CTCAE) and Hematological and Blood Chemistry Parameters) [ Time Frame: Adverse events: from date treatment consent signed to 28 days after last dose of study drug; hematology/blood chemistry tests: at baseline and between Day 11-14 of each cycle of a total of 135 two-week cycles. ]
The adverse events (AEs) were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and their severity graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The following subsets of AEs were considered: serious AEs, AEs with CTCAE grade 3-5, AEs with a relationship to study treatment classified by the Investigator as possible or probable or definite and AEs reported as leading to discontinuation from treatment.
Laboratory test values were graded according to the NCI CTCAE scale, v3.0, whenever possible. For each laboratory test included in the NCI CTCAE system, the incidence of abnormalities was evaluated by considering the worst occurrence for each patient throughout the whole treatment period.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)
- Presence of measurable disease
- Age >=18 years
- ECOG performance status 0-1
- Negative pregnancy test (if female in reproductive years)
- Use of effective contraceptive methods if men and women of child producing potential
- Adequate liver function Total Serum Bilirubin <=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) <=2.5ULN (if liver metastases are present, then <=5ULN is allowed) ALP <=2.5ULN (if liver and/or bone metastases are present, then <=5ULN is allowed)
- Adequate renal function Serum Creatinine <=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula > 60 mL/min.
- Adequate hematologic status ANC >=1,500cells/mm3 Platelet Count >=100,000cells/mm3 Hemoglobin >=9.0g/dL
- Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)
- Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade <=1
Exclusion Criteria:
- Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
- Grade >1 retinopathy
- Known brain metastases
- Known active infections
- Pregnant or breast feeding women
- Diabetes mellitus uncontrolled
- Gastrointestinal disease that would impact on drug absorption
- Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline
- Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01011439
United States, Arizona | |
TGen Clinical Research Services at Scottsdale Healthcare | |
Scottsdale, Arizona, United States, 85258 | |
United States, Maryland | |
NIH, Center for Cancer Research, Medical Oncology | |
Bethesda, Maryland, United States, 20892 | |
France | |
Hopital Larrey | |
Toulouse Cedex, France, 31059 | |
Institut de cancerologie Gustave Roussy | |
Villejuif Cedex, France, 94805 | |
Italy | |
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano | |
Milano, (mi), Italy, 20133 | |
Azienda Ospedaliera San Luigi Gonzaga | |
Orbassano, Italy, 10043 |
Principal Investigator: | Glen Weiss, MD | Scottsdale Clinical Research Institute, USA | |
Principal Investigator: | Benjamin Besse, MD | Institut Gustave Roussy, Villejuif, France | |
Principal Investigator: | Julien Mazières, MD | Hopital Larrey CHU, Toulouse, France | |
Principal Investigator: | Silvia Novello, MD | Ospedale San Luigi Gonzaga, Orbassano, Italy | |
Principal Investigator: | Arun Rajan, MD. | National Cancer Institute (NCI) | |
Principal Investigator: | Marina C Garassino, MD | Fondazione IRCCS Istituto Nazionale dei Tumori di Milano |
Documents provided by Tiziana Life Sciences, PLC:
Responsible Party: | Tiziana Life Sciences, PLC |
ClinicalTrials.gov Identifier: | NCT01011439 |
Other Study ID Numbers: |
CDKO-125a-006 2009-014338-79 ( EudraCT Number ) |
First Posted: | November 11, 2009 Key Record Dates |
Results First Posted: | October 16, 2018 |
Last Update Posted: | February 6, 2019 |
Last Verified: | January 2019 |
B3 and C malignant thymoma |
Carcinoma Thymoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Complex and Mixed Thymus Neoplasms |
Thoracic Neoplasms Neoplasms by Site Lymphatic Diseases Maleic acid Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |